HK1203561A1 - Stabilization of the anti-cd20 antibody rituximab cd20 - Google Patents

Stabilization of the anti-cd20 antibody rituximab cd20

Info

Publication number
HK1203561A1
HK1203561A1 HK15104128.0A HK15104128A HK1203561A1 HK 1203561 A1 HK1203561 A1 HK 1203561A1 HK 15104128 A HK15104128 A HK 15104128A HK 1203561 A1 HK1203561 A1 HK 1203561A1
Authority
HK
Hong Kong
Prior art keywords
stabilization
antibody rituximab
rituximab
antibody
Prior art date
Application number
HK15104128.0A
Other languages
Chinese (zh)
Inventor
羅斯瑪麗．威爾頓
Original Assignee
Therapeutic Proteins Internat Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Proteins Internat Llc filed Critical Therapeutic Proteins Internat Llc
Publication of HK1203561A1 publication Critical patent/HK1203561A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15104128.0A 2012-01-19 2015-04-29 Stabilization of the anti-cd20 antibody rituximab cd20 HK1203561A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/021888 WO2013109279A2 (en) 2012-01-19 2012-01-19 Stabilization of the anti-cd20 antibody rituximab

Publications (1)

Publication Number Publication Date
HK1203561A1 true HK1203561A1 (en) 2015-10-30

Family

ID=48799789

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104128.0A HK1203561A1 (en) 2012-01-19 2015-04-29 Stabilization of the anti-cd20 antibody rituximab cd20

Country Status (7)

Country Link
EP (1) EP2804952A4 (en)
JP (1) JP2015506687A (en)
CN (1) CN104204217A (en)
AU (1) AU2012366290A1 (en)
CA (1) CA2861428A1 (en)
HK (1) HK1203561A1 (en)
WO (1) WO2013109279A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163630A1 (en) * 2012-04-27 2013-10-31 Bioatla Llc. Modified antibody regions and uses thereof
ES2699599T3 (en) * 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Fc variants
AU2015211480B2 (en) * 2014-01-31 2020-05-14 Kling Biotherapeutics B.V. Means and methods for producing stable antibodies
AU2017217814A1 (en) * 2016-02-10 2018-08-23 Cayman Chemical Company Incorporated Anti-citrullinated HLA polypeptide antibodies and uses thereof
CN107987160A (en) * 2016-10-26 2018-05-04 无锡科捷诺生物科技有限责任公司 A kind of monoclonal antibody of no fucosylation
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
KR20220144797A (en) * 2019-12-31 2022-10-27 나브로겐 인코포레이티드 Compositions and Uses of Engineered Monoclonal Antibodies Refractory to Tumor Immunosuppressive Factors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249760B2 (en) * 2000-03-30 2005-04-21 Dyax Corp. Mucin-1 specific binding members and methods of use thereof
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7232888B2 (en) * 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
EP2301966A1 (en) * 2002-12-16 2011-03-30 Genentech, Inc. Immunoglobulin variants and uses thereof
US7833731B2 (en) * 2004-03-31 2010-11-16 Canon Kabushiki Kaisha Gold-binding protein and use thereof
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
WO2010008690A1 (en) * 2008-07-14 2010-01-21 Uchicago Argonne, Llc Methods for systematic control of protein stability
WO2010011697A1 (en) * 2008-07-21 2010-01-28 Immunomedics Inc. Structural variants of antibodies for improved therapeutic characteristics

Also Published As

Publication number Publication date
EP2804952A4 (en) 2015-09-09
AU2012366290A1 (en) 2014-08-07
CA2861428A1 (en) 2013-07-25
JP2015506687A (en) 2015-03-05
EP2804952A2 (en) 2014-11-26
WO2013109279A2 (en) 2013-07-25
CN104204217A (en) 2014-12-10
WO2013109279A3 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
IL269528A (en) Anti-fcrh5 antibodies
IL235985A0 (en) Immunoconjugates comprising anti-cd22 antibodies
IL235807A0 (en) Immunoconjugates comprising anti-cd79b antibodies
IL235989A0 (en) Immunoconjugates comprising anti-cd79b antibodies
ZA201500457B (en) Anti-kit antibodies and uses thereof
IL235987A0 (en) Immunoconjugates comprising anti-cd22 antibodies
GB201322583D0 (en) Antibodies
HK1203561A1 (en) Stabilization of the anti-cd20 antibody rituximab cd20
EP2841459A4 (en) Anti-cd22 antibodies
HK1220142A1 (en) Antibodies
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
EP2994759A4 (en) Stabilization of labile analytes in reference materials
IL240440A0 (en) Highly galactosylated anti-her2 antibodies and uses thereof
IL245488B (en) Anti-ccl17 antibodies
SG11201505220VA (en) Prevention & treatment of neuropathy
GB201312226D0 (en) Improved antibodies
ZA201507251B (en) Antibodies targeting m-csf
HRP20180832T1 (en) Compounds for enhancing the cognitive function
EP2852411A4 (en) Anti-ccl2 antibodies for treatment of scleroderma
GB201311051D0 (en) Fastening regions of material together
GB201318283D0 (en) Antibodies